FDA approves standalone at-home sample collection kit

(Reuters) – The U.S. Food and Drug Administration on Saturday approved a standalone at-home sample collection kit for COVID-19 diagnostic testing.

The regulator has given an emergency use authorization (EUA) to Everlywell Inc, a health and wellness company, for its COVID-19 test home collection kit.

Everlywell launched the COVID-19 at-home collection kit last month.

Reporting by Maria Ponnezhath in Bengaluru; Editing by Matthew Lewis

View original article here Source

Related Posts